BioCryst Stock Takes a Hit as Peramivir Trial Extended

Stock in BioCryst Pharmaceuticals Inc. fell 6.7 percent Thursday after the Research Triangle Park, N.C.-based company said it would extend the enrollment period for a trial of peramivir for hospitalized influenza patients. The company revised its clinical trial design for the study in response to feedback from the Biomedical Advanced Research and Development Authority (BARDA).